Event Videos

Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality

http://www.ncbi.nlm.nih.gov/pubmed/23676440
Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Treatment of patients withdual hepatitis C and B by peginterferon α and ribavirin reduced risk ofhepatocellular carcinoma and mortality. Gut. 2014;63(3):506-14.

Abstract

OBJECTIVE:

Whether peginterferon α and ribavirin combination therapy reduces risk of hepatocellular carcinoma (HCC) or improves survival in patients dual-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) is unknown. Since it is ethically impossible to conduct a randomised trial to learn the long-term efficacy, we rely upon the large database to explore the effectiveness of combination therapy among dual-infected patients.

DESIGN:

Published on: 
Mar-2014
Read more

Factors that predict mortality in children with Wilson disease associated acute liver failure and comparison of Wilson disease specific prognostic indices

http://www.ncbi.nlm.nih.gov/pubmed/24033813

Devarbhavi H, Singh R, Adarsh CK, Sheth K, Kiran R, Patil M. Factors that predict mortality in children with Wilson disease associated acute liver failure and comparison of Wilson disease specific prognostic indices. J Gastroenterol Hepatol. 2014 Feb; 29(2): 380-6.

Abstract

BACKGROUND AND AIMS:

Wilson disease (WD) associated acute liver failure (ALF) affects children more than adults. The predictors of mortality and outcome in patients without encephalopathy are not clear. We investigated the ability of prognostic factors and various models including model for end-stage liver disease (MELD) to predict mortality among children with WD and ALF.

METHODS:

Published on: 
Feb-2014
Read more

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with Chronic Hepatitis C

http://www.ncbi.nlm.nih.gov/pubmed/24316262
Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L,Brown RS Jr, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D,Bertelsen K, Witek J. Telaprevir twice daily is noninferior to telaprevir every 8hours for patients with chronic hepatitis C. Gastroenterology. 2014Mar;146(3): 744-753.

Abstract

BACKGROUND & AIMS:

We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis.

METHODS:

Published on: 
Mar-2014
Read more

Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis

http://www.ncbi.nlm.nih.gov/pubmed/24038116

Lisotti A, Azzaroli F, Buonfiglioli F, Montagnani M, Cecinato P, Turco L, Calvanese C, Simoni P, Guardigli M, Arena R, Cucchetti A, Colecchia A, Festi D, Golfieri R, Mazzella G. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology. 2014 Feb; 59(2): 643-50.

Abstract

Published on: 
Feb-2014
Read more

The contribution of viral hepatitis to the burden of chronic liver disease in the United States

http://www.ncbi.nlm.nih.gov/pubmed/24445570
Roberts HW, Utuama OA, Klevens M, Teshale E, Hughes E, Jiles R. Thecontribution of viral hepatitis to the burden of chronic liver disease in theUnited States. Am J Gastroenterol. 2014;109(3):387-93.

Abstract

OBJECTIVES:

Chronic liver disease (CLD) is increasingly recognized as a major public health problem. However, in the United States, there are few nationally representative data on the contribution of viral hepatitis as an etiology of CLD.

METHODS:

Published on: 
Mar-2014
Read more

Effect of molecular adsorbents recirculating system treatment in children with acute liver failure caused by Wilson disease.

http://www.ncbi.nlm.nih.gov/pubmed/24458219

Rustom N, Bost M, Cour-Andlauer F, Lachaux A, Brunet AS, Boillot O, Bordet F, Valla F, Richard N, Javouhey E. Effect of molecular adsorbents recirculating system treatment in children with acute liver failure caused by Wilson disease. J Pediatr Gastroenterol Nutr. 2014 Feb; 58(2): 162-6.

Abstract

OBJECTIVES:

Because fulminant Wilson disease (WD) has an extremely poor prognosis, the use of liver support that can bridge patients to liver transplantation is lifesaving. We report the experience of albumin dialysis in acute liver failure (ALF) caused by WD in children.

METHODS:

Published on: 
Feb-2014
Read more

Improved outcomes in liver transplantation in children with acute liver failure

http://www.ncbi.nlm.nih.gov/pubmed/23942007

Oh SH, Kim KM, Kim DY, Kim Y, Song SM, Lee YJ, Park SJ, Yoon CH, Ko GY, Sung
KB, Hwang GS, Choi KT, Yu E, Song GW, Ha TY, Moon DB, Ahn CS, Kim KH, Hwang S,
Park KM, Lee YJ, Lee SG. Improved outcomes in liver transplantation in children
with acute liver failure. J Pediatr Gastroenterol Nutr. 2014 Jan; 58(1): 68-73.

Abstract

OBJECTIVE:

The aim of our study was to review the experiences of a living donor-dominant transplantation program for children with acute liver failure (ALF).

METHODS:

Data were derived from the retrospective chart review of 50 children with ALF in a major liver center in the Republic of Korea.

RESULTS:

Published on: 
Jan-2014
Read more
« first ‹ previous … 147 148 149 150 151 152 153 154 155 … next › last »

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: